STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this activity, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiwess, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.
Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
Upon completion of this activity, participants should be able to:
- Evaluate the implications of hormone receptor and HER2 expression status for prognostication and treatment selection in TNBC
- Differentiate the pathological characteristics of the various types of TNBC
- Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
- Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies
Ira J. Bleiweiss, MD
Professor of Pathology and Laboratory Medicine
Perelman School of Medicine
Chief of Breast Pathology
Hospital of the University of Pennsylvania
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women's Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
There is no fee to participate in or claim CME/NCPD credit for this activity.
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
i3 Health designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge/Practice Assessment MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.25 hours of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 1.25 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.1 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.25 ANCC contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.25 ILNA points toward:
- Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
- Diagnosis and Staging (CBCN®)
- Nursing Practice (CBCN®)
- Oncology Nursing Practice (OCN®)
- Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
- Treatment (OCN®, CBCN®, AOCNP®, CPHON®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Ira J. Bleiweiss, MD, has no relevant financial relationships to disclose.
Sara M. Tolaney, MD, MPH, discloses that she has served on an advisory board/panel for 4D Pharma, ARC Therapeutics, Artios, AstraZeneca, Bayer, BeyondSpring, Bristol Myers Squibb, Eisai, Genentech/Roche, Gilead, Incyte, Lilly, Menarini/Stemline, Merck, Myovant, Novartis, Pfizer, Reveal Genomics, Sanofi, Seagen, Umoja Biopharma, Zentalis, and Zymeworks; that she has served as a consultant for Aadi Bio, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, CytomX, Daiichi Sankyo, Eisai, Genentech Roche, Gilead, Lilly, Menarini/Stemline, Merck, Novartis, OncXerna, Pfizer, Seagen, and Zetagen; and that she has received grants/research support from AstraZeneca, Bristol Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi, and Seagen.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Aggregate participant data will be shared with commercial supporters of this activity.